Skip to main content

Table 1 Patient characteristics

From: Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

Number of patients 35
Sex
 Male (%) 25 (71.4)
 Female (%) 10 (28.6)
Age (years) median range 62.5 (45–81)
Total cycles median (range) 6 (5–8)
Cumulative activity (GBq) median (range) 44 (33.5–47)
Primary tumor
 Small intestinal (%) 23 (65.7)
 Lungs (%) 5 (14.3)
 Cancer of unknown primary (%) 4 (11.4)
 Rectal (%) 1 (2.9)
 Gastric (%) 1 (2.9)
 Paraganglioma (%) 1 (2.9)
Ki-67 proliferation index
  < 3% 7 (20.0)
 3–20% 22 (62.9)
 Not evaluable 6 (17.1)
Metastases (%)
 Liver (%) 31 (88.6)
 Lymph nodes (%) 12 (34.3)
 Bone (%) 12 (34.3)
 Peritoneal (%) 7 (14.3)